Nahla B Gadalla
Overview
Explore the profile of Nahla B Gadalla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Windle S, Lane K, Gadalla N, Liu A, Mu J, Caleon R, et al.
Int J Parasitol Drugs Drug Resist
. 2020 Nov;
14:208-217.
PMID: 33197753
Background: Lumefantrine and mefloquine are used worldwide in artemisinin-based combination therapy (ACT) of malaria. Better understanding of drug susceptibility and resistance is needed and can be obtained from studies of...
2.
Schousboe M, Ranjitkar S, Rajakaruna R, Amerasinghe P, Morales F, Pearce R, et al.
PLoS Negl Trop Dis
. 2015 Nov;
9(11):e0004196.
PMID: 26539821
Background: Chloroquine combined with primaquine has been the recommended antimalarial treatment of Plasmodium vivax malaria infections for six decades but the efficacy of this treatment regimen is threatened by chloroquine...
3.
Gadalla N, Tavera G, Mu J, Kabyemela E, Fried M, Duffy P, et al.
Malar J
. 2015 Apr;
14:129.
PMID: 25890383
Background: A report of the chloroquine and amodiaquine resistance pfcrt-SVMNT haplotype in Tanzania raises concern about high-level resistance to the artesunate-amodiaquine combination treatment widely employed in Africa. Mutations in the...
4.
Gadalla N, Malmberg M, Adam I, Oguike M, Beshir K, Elzaki S, et al.
J Antimicrob Chemother
. 2014 Sep;
70(1):116-23.
PMID: 25253286
Objectives: Polymorphisms in the lysosomal transporter encoded by the pfcrt gene directly impact on Plasmodium falciparum susceptibility to aminoquinolines. The Lys76Thr mutation is the critical change conferring chloroquine resistance in...
5.
Venkatesan M, Gadalla N, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al.
Am J Trop Med Hyg
. 2014 Jul;
91(4):833-843.
PMID: 25048375
Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) and P. falciparum...
6.
Henriques G, Hallett R, Beshir K, Gadalla N, Johnson R, Burrow R, et al.
J Infect Dis
. 2014 Jul;
210(12):2001-8.
PMID: 24994911
Background: The efficacy of artemisinin-based combination therapy (ACT) for Plasmodium falciparum malaria may be threatened by parasites with reduced responsiveness to artemisinins. Among 298 ACT-treated children from Mbita, Kenya, submicroscopic...
7.
Mosha J, Sturrock H, Greenwood B, Sutherland C, Gadalla N, Atwal S, et al.
Malar J
. 2014 Feb;
13:53.
PMID: 24517452
Background: Within affected communities, Plasmodium falciparum infections may be skewed in distribution such that single or small clusters of households consistently harbour a disproportionate number of infected individuals throughout the...
8.
van Schalkwyk D, Burrow R, Henriques G, Gadalla N, Beshir K, Hasford C, et al.
Malar J
. 2013 Sep;
12:320.
PMID: 24028570
Background: The screening of lead compounds against in vitro parasite cultures is an essential step in the development of novel anti-malarial drugs, but currently relies on laboratory parasite lines established...
9.
Gadalla N, Abdallah T, Atwal S, Sutherland C, Adam I
Malar J
. 2013 Jul;
12:255.
PMID: 23870667
Background: Artesunate/sulphadoxine-pyrimethamine (AS/SP) has been the first-line treatment for falciparum malaria in Sudan since 2004. The impact of this combination on anti-malarial resistance-associated molecular markers has not been investigated. In...
10.
Gadalla N, Adam I, Elzaki S, Bashir S, Mukhtar I, Oguike M, et al.
Antimicrob Agents Chemother
. 2011 Sep;
55(11):5408-11.
PMID: 21896916
Molecular markers for surveillance of Plasmodium falciparum resistance to current antimalarials are sorely needed. A 28-day efficacy study of artemether-lumefantrine in eastern Sudan identified 5 treatment failures among 100 evaluable...